Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC Obtains Key Patent for Anti-Cancer Compound Resminostat in China

Published: Wednesday, October 03, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
Due to large market size and high occurrence of liver cancer, China is of key strategic importance for the further development and commercialization of resminostat.

4SC AG has announced that the company has significantly enhanced the patent protection for its lead anti-cancer compound resminostat.

4SC has received a notification of allowance for patent protection of resminostat in China, the third largest pharmaceutical market worldwide, from the Chinese patent authority (SIPO).

Thus the granting of the composition-of-matter patent is now imminent. The patent, having a very broad extent of protection, covers the composition of matter of resminostat, pharmaceutical compositions comprising resminostat, and its therapeutic use in cancer and other areas.

China is by far the country with the highest incidence rates of liver cancer in the world and, therefore, of key importance for the further development and commercialization of resminostat.

Liver cancer (hepatocellular carcinoma, HCC), a disease with a high medical need and only very few treatment options available, is one of the indications currently addressed with resminostat in clinical Phase II trials.

Resminostat has recently shown excellent Phase II results in this indication, achieving a median overall survival (OS) of 8.0 months in second-line HCC patients in the combination treatment with sorafenib (Nexavar®).

According to the World Health Organization (GLOBOCAN 2008), there were more than 400,000 incidences of liver cancer in China in 2008 - accounting for 14% of all new cases of cancer in this country.

The number of new cases of liver cancer per year in China is expected to grow to 550,000 by the year 2020. According to IMS Health, China - with a total volume of 50 bn. USD - is the world's third largest pharmaceutical market behind the USA and Japan.

Until 2020, analysts estimate a further growth of this sector in China by 18 to 25% per year. Due to the high occurrence of hepatitis infections, liver cancer has particularly high incidence rates in the whole Asian-Pacific region.

4SC entered into a first development and commercialization partnership in this growth region in April 2011, when it granted an exclusive license for resminostat to Yakult Honsha, the Japanese market leader for gastrointestinal cancer therapies.

Dr. Ulrich Dauer, Chief Executive Officer of 4SC AG, commented: 'We are very pleased to obtain this key patent for our lead anti-cancer compound resminostat in China. This bolsters our competitive position in this large and attractive market as well as in the whole Asian-Pacific region, which is commercially very important for the development of resminostat in the indication of liver cancer (HCC). After we have recently shown excellent overall survival data in a Phase II trial in patients with advanced HCC, we are currently in talks with regulatory agencies and potential partners to prepare a global registration trial with resminostat in this indication. We believe that the enhanced patent protection in China will serve to further advance the successful progress of these talks with potential partners.'


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
Friday, June 26, 2015
4SC Signs Licensing and Development Agreement with Menarini
Licensing partnership for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan.
Thursday, April 16, 2015
Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join 4SC AG
Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn.
Saturday, January 17, 2015
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucial role in cell division and tumour growth.
Friday, December 12, 2014
4SC Further Strengthens Patent Protection for its Lead Compound Resminostat
US Patent granted for the manufacturing process of resminostat.
Tuesday, October 21, 2014
4SC's Partner Yakult Honsha Completes Phase I Part of Clinical Study with Resminostat in NSCLC Patients
Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian NSCLC patients.
Saturday, October 11, 2014
CRELUX and 4SC Discovery Awarded Research Grant
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme.
Thursday, July 24, 2014
4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
Dr Erich Enghofer joins 4SC in the newly created position of Executive Vice President.
Friday, July 04, 2014
4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study
Company will present data from Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO.
Friday, May 30, 2014
4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC's Partner Yakult Honsha Starts Clinical Phase I/II Study with Resminostat in NSCLC
The Phase I/II study will investigate safety and efficacy of resminostat/docetaxel combination vs. docetaxel alone as a novel treatment option for patients with advanced, metastatic, or recurrent NSCLC.
Thursday, July 25, 2013
4SC Expands Patent Protection for Epigenetic Anti-Cancer Compound
4SC AG announced that the company has significantly expanded international patent protection for 4SC-202 in the USA, China and Hong Kong.
Monday, July 15, 2013
4SC Gives Update on the Clinical Development of its Lead Cancer Compound Resminostat
Data from completed Phase I part of SHORE study confirms the safety of the resminostat FOLFIRI combination and showing encouraging signs of clinical benefit
Thursday, May 30, 2013
4SC Reports Positive Data from Clinical Phase I trial with 4SC-205 in Cancer Patients
All primary objectives of the clinical study achieved.
Thursday, March 28, 2013
Scientific News
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!